The Non-Financial Ledger: Betrayal of Trust

This be a story about the violation of trust between a caregiver and a corporation they believed was an ally. Dog owners, who the lawsuit notes often treat their pets “as their children (or better),” are a vulnerable market. They are driven by love, not by profit margins. They are willing to pay a premium for any product that promises to alleviate the pain of a loyal companion.

FoodScience LLC, through its VetriScience brand, weaponized that love. They allegedly converted a weak, 18-year-old “pilot study” on seven dogs into a “clinically proven” seal of approval. This seal was then stamped across packaging and websites, selling not just a supplement, but hope. The real product was a false sense of security, purchased with hard-earned cash by people desperate to help a suffering member of their family.

The Anatomy Of The Lie

VetriScience’s central claim for its GlycoFlex supplements is that they are “clinically proven” to increase canine hind leg strength by up to 41% in four weeks. Legal filings reveal this claim is built on a foundation of sand. The evidence cited is a 2006 “pilot study” conducted at Washington State University. A “pilot study” is an exploratory, small-scale experiment. It is not, by any scientific definition, a clinical proof.

The study itself is even more damning. It involved only seven dogs. These dogs had osteoarthritis artificially induced via surgery and chemicals. Of these seven lab-induced cases, the study observed that only 3 dogs “had a significant improvement in lameness.” The remaining four dogs, the majority of the test subjects, had no significant increase in hind leg strength. The company took the average strength increase from the three successful subjects and marketed it as a universal promise.

“VetriScience has never clinically tested its GlycoFlex supplement…VetriScience’s Clinically Proven Claim in its packaging and marketing materials is demonstrably false.”

Legal Receipts: The Official Allegations

This action seeks to redress the false, misleading, and deceptive advertising and packaging claims that VetriScience has made in connection with the sale of its GlycoFlex® Plus and GlycoFlex Stage 3… canine joint support supplements that purports to be “clinically proven”…

Complaint, Paragraph 1

The pilot study observed that only 3 of the 7 dogs “had a significant improvement in lameness” and an average 41% increase in hind leg strength, meaning 4 of the 7 dogs had no significant increase in hind leg strength.

Complaint, Paragraph 2

…it is clear that VetriScience never believed its own Clinically Proven Claim. It waited approximately eight years after the 2006 Pilot Study to timidly claim in 2014 that GlycoFlex was “clinically researched.” In 2018, however, VetriScience threw all caution and honesty to the wind and boldly claimed that the 2006 Pilot Study clinically proved that GlycoFlex was an effective treatment…

Complaint, Paragraph 3

An advertiser’s health-related claims about the efficacy of a product must “be supported with ‘competent and reliable scientific evidence,’” which the Federal Trade Commission (the “FTC”) defines as “‘tests, analyses, research, studies, or other evidence based on the expertise of professionals in the relevant area, that have been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results.’”

Complaint, Paragraph 17

Societal Impact Mapping

Public Health (Canine)

This deception is a direct threat to the health of pets. An owner who buys GlycoFlex, believing it is a “clinically proven” treatment, may delay or forgo seeking proper veterinary care or proven medical interventions. The false advertising creates a dangerous illusion of treatment, allowing an animal’s condition to potentially worsen while the owner believes they are providing effective care.

Economic Inequality

The lawsuit explicitly states that dog owners “are willing to pay a premium for joint support supplements that are scientifically proven to be effective.” VetriScience, a company ultimately owned by the private equity firm Wind Point Partners, exploits this willingness. It’s a classic case of wealth transfer: working people’s money, spent out of love and concern, is funneled into corporate and investor pockets based on a fraudulent claim. The premium price is not for a better product; it is for better, more deceptive marketing.

Market Distortion

In the crowded $1.6 billion pet supplement market, VetriScience’s “clinically proven” lie creates what the complaint calls “pneumatic pressure” on competitors. Honest companies that cannot make such a bold claim because they lack the “proof” (or the audacity to fabricate it from a pilot study) are at a significant competitive disadvantage. This behavior poisons the entire market, rewarding deception and punishing integrity.

What Now? The Watchlist and The Resistance

This is not just one company; it’s a system. The lawsuit traces VetriScience’s ownership through a chain of LLCs and LPs directly to the private equity firm Wind Point Partners. This is the financial engine that demands returns, creating the pressure that leads to such flagrant marketing deception.

The Resistance

Accountability does not come from corporations or regulators alone. It comes from us. The lawsuit lists Amazon, Chewy, Target, Petco, and Walmart as major distributors. Your purchasing power is your voice. Consider supporting local, independent pet supply stores where you can have a direct conversation about product sourcing and efficacy.

Demand transparency. Ask questions. Read the back of the package, and if you see a tiny asterisk next to a bold claim, find out what it’s hiding. Share this investigation. The most powerful tool we have is a network of informed people who refuse to let their love and trust be monetized by a lie.